A chronic porcine post-MI HF model initiating therapy 1 month after infarction demonstrated that monthly IV CDR132L (5 mg·kg−1) for 3 or 5 months improved systolic function (+7–8% absolute vs baseline/placebo-corrected), attenuated LVESV progression, improved diastolic indices (dP/dt_min and EDPVR), reduced left-atrial volume, and lowered NT-proBNP, with sustained target engagement and no drug-related safety signals—thereby supporting a clinically practical monthly regimen [47]. Here, NPPB is linked to infarction.